Published in Cancer Weekly, October 12th, 2004
In their study, they compared paclitaxel's inhibitory effect on heat shock protein 27 (HSP27) in ovarian and uterine cancer cell lines with that of other anti-cancer drugs that have different mechanisms of action.
"BG-1 ovarian cancer cells and HeLa uterine cancer cells were treated with a tubulin depolymerization inhibitor (paclitaxel), a topoisomerase-II inhibitor (etoposide), and two tubulin polymerization inhibitors (colcemid and vincristine). Cell kills were evaluated by counting the number of cells....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.